Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial with TRIOLEX (HE3286) in Rheumatoid Arthritis Patients

07-Aug-2008

Hollis-Eden Pharmaceuticals, Inc. announced that it has commenced a Phase I/II open label dose ranging clinical trial with its investigational oral drug candidate TRIOLEX(TM) (HE3286) in patients diagnosed with rheumatoid arthritis (RA) and receiving a stable dose of methotrexate, the current standard of care in RA.

The purpose of the Phase I/II clinical trial is to evaluate the safety and tolerance of TRIOLEX when administered orally for 28 days at three different dose levels. The study will also evaluate the pharmacokinetics (PK) and metabolism profiles of methotrexate and TRIOLEX when used in combination, and assess any potential anti-inflammatory activity of TRIOLEX.

"The commencement of this clinical trial caps six years of international collaborations with world renowned experts working on the development of a new treatment for RA," commented Dr. Dominick L. Auci, Director of Allergy, Autoimmunity and Inflammation at Hollis-Eden Pharmaceuticals. "This body of work, presented over the years at numerous international meetings and published in peer reviewed journals, clearly documents the remarkable activity of TRIOLEX across several animal models of RA, each emphasizing different aspects of the pathophysiology thought to drive the human disease. We are particularly excited to begin this trial because TRIOLEX, without being immune suppressive, has consistently performed as well or better than the biologics in these models and works where methotrexate fails."

https://www.bionity.com/en/news/85508/hollis-eden-pharmaceuticals-commences-phase-i-ii-clinical-trial-with-triolex-he3286-in-rheumatoid-arthritis-patients.html